Company Overview and News

 
Alacer Gold Announces Release Date for Third Quarter 2018 Operational and Financial Results Conference Call

2018-10-11 globenewswire
TORONTO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) [TSX: ASR and ASX: AQG] plans to release its third quarter 2018 operating results, financial statements and the related management’s discussion and analysis before the TSX market opens on Tuesday, October 30, 2018 (North America).
AQG ALIAF ASR ALACF

 
Alacer Gold Announces Third Quarter Production Results

2018-10-04 globenewswire
TORONTO, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Company”) [TSX: ASR and ASX: AQG] announces unaudited third quarter 2018 production of 26,160 ounces from the Çöpler Gold Mine. The Company expects to meet the lower end of the full-year consolidated production guidance of 160,000 to 230,000 ounces. Third quarter 2018 financial and operating results and the related management’s discussion and analysis are planned to be released on October 30, 2018 (North America) / October 31, 2018 (Australia).
AQG ALIAF ASR ALACF

 
Alacer Gold Announces the Processing of Oxide Ore Through the Newly Constructed Çöpler Sulfide Plant

2018-09-04 globenewswire
TORONTO, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Company”) [TSX: ASR and ASX: AQG] announces the processing of the first oxide ore through the crushing and grinding circuit over the past weekend. The remainder of the plant, including the acidulation, pressure oxidation and counter current decantation circuits (collectively the “Sulfide Circuit”), will be started once the Sulfide Circuit commissioning is complete and the oxide circuit is fully operational and stabilized.
AQG ALIAF ASR ALACF

 
Alacer Gold Corp's (ALIAF) CEO Rodney Antal on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
Welcome to the Alacer Gold Second Quarter 2018 Operating and Financial Results Conference Call and Webcast. As a reminder all participants are in listen-only mode and the conference is being recorded. After the presentation there will be an opportunity to ask questions. [Operator Instructions].
ALIAF AQG ASR ALACF AI

 
Alacer Gold Announces Additional Positive Drill Results for the Ardich Gold Prospect, Including 50.2 Meters at 3.01 Grams Per Tonne Gold Near Surface

2018-07-25 globenewswire
TORONTO, July 25, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) and (ASX:AQG) is pleased to announce additional positive drill results for the Ardiç (Ardich) gold prospect. In addition to the previously reported 18 holes1, a further 25 drill holes have been completed with a majority intersecting predominantly oxide mineralization with impressive gold grades. Key results include holes AR41 with 50.
AQG ALIAF ASR BVVBY MALRY BVINV ALACF MALRF MIN BVI

 
Alacer Gold Announces Release Date for Second Quarter 2018 Operational and Financial Results Conference Call

2018-07-16 globenewswire
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) and (ASX:AQG) plans to release its second quarter 2018 operating results, financial statements and the related management’s discussion and analysis before the TSX market opens on Tuesday, July 31, 2018 (North America).
AQG ALIAF ASR ALACF

 
Alacer Gold Announces an Increase to 2018 Oxide Plant Production Guidance at Reduced All-In Sustaining Costs and Reaffirms Sulfide Plant Production Guidance & Schedule

2018-07-09 globenewswire
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Company”) (TSX:ASR) (ASX:AQG) announces an increase to its 2018 oxide plant production guidance to 110,000 – 130,000 ounces at reduced oxides All-in Sustaining Costs of $650 – $700 per ounce1. Production guidance from the sulfide plant remains unchanged at 50,000 – 100,000 ounces, with the construction of the plant remaining on schedule and under budget.
AQG ALIAF ASR ALACF

1
Blackham Resources bolsters Board with appointment of experienced mining engineer

2018-06-22 proactiveinvestors.com.au
Blackham Resources Ltd (ASX:BLK) has strengthened its Board with the appointment of experienced mining engineer Tony James as a non-executive director.
AQG ALIAF CRNRF BKHRF ASR DRM BLK ALACF CRB

1
Alacer Gold Announces Results of Annual and Special Meeting of Shareholders

2018-06-08 globenewswire
TORONTO, June 08, 2018 (GLOBE NEWSWIRE) -- Alacer Gold Corp. (“Alacer” or the “Corporation”) (TSX:ASR) (ASX:AQG) is pleased to announce the results of its 2018 Annual and Special Meeting of Shareholders (the “Meeting”) held on June 7, 2018 in Denver, Colorado.
AQG ALIAF ASR ALACF

19
CANADA STOCKS-Energy shares drag TSX lower as oil prices slip

2018-06-06 reuters
June 6 (Reuters) - Canada’s main stock index edged lower on Wednesday, weighed down by energy stocks that slipped due to lower oil prices.
ALIAF AQG DRG.UN IVPAF TWMJF ACB ASR WEED ACBFF IVN ALACF CGC

1
Alacer Gold - 2 Hidden Factors Driving The Company's Value Up

2018-05-22 seekingalpha
In Q3 2018 Alacer Gold will start producing gold from the sulfide zone of the Copler mine.
ALIAF AQG ASR ALACF

1
Alacer Gold Corp's (ALIAF) CEO Rodney Antal on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Welcome to the Alacer Gold First Quarter 2018 Operating and Financial Results Conference call. As a reminder all participants are in listen-only mode and the conference is being recorded. After the presentation there will be an opportunity to ask questions. [Operator Instructions].
ALIAF AQG ASR ALACF

15
Is Palladium Losing Strength against Gold?

2018-05-01 marketrealist
Palladium has been the weakest among the four precious metals on a YTD (year-to-date) basis. Palladium has seen a YTD fall of 8.7%. The fall in car demand in China may be the reason behind the massive palladium price crash.
ALIAF AQG ELD ASR ALACF EGO

1
Alacer Gold Corp. 2018 Q1 - Results - Earnings Call Slides

2018-05-01 seekingalpha
The following slide deck was published by Alacer Gold Corp. in conjunction with their 2018 Q1 earnings call.
ALIAF AQG ASR ALACF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 010679108